Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow

Markt, Patrick; Feldmann, Clemens; Rollinger, Judith Maria; Raduner, Stefan; Schuster, Daniela; Kirchmair, Johannes; Distinto, Simona; Spitzer, Gudrun Maria; Wolber, Gerhard; Laggner, Christian; Altmann, Karl-Heinz; Langer, Thierry; Gertsch, Jürg (2009). Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. Journal of medicinal chemistry, 52(2), pp. 369-78. Easton, Pa.: American Chemical Society 10.1021/jm801044g

Full text not available from this repository. (Request a copy)

Cannabinoid receptor 2 (CB(2) receptor) ligands are potential candidates for the therapy of chronic pain, inflammatory disorders, atherosclerosis, and osteoporosis. We describe the development of pharmacophore models for CB(2) receptor ligands, as well as a pharmacophore-based virtual screening workflow, which resulted in 14 hits for experimental follow-up. Seven compounds were identified with K(i) values below 25 microM. The CB(2) receptor-selective pyridine tetrahydrocannabinol analogue 8 (K(i) = 1.78 microM) was identified as a CB(2) partial agonist. Acetamides 12 (K(i) = 1.35 microM) and 18 (K(i) = 2.1 microM) represent new scaffolds for CB(2) receptor-selective antagonists and inverse agonists, respectively. Overall, our pharmacophore-based workflow yielded three novel scaffolds for the chemical development of CB(2) receptor ligands.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Biochemistry and Molecular Medicine

UniBE Contributor:

Gertsch, Jürg




American Chemical Society




Factscience Import

Date Deposited:

04 Oct 2013 15:12

Last Modified:

04 May 2014 23:23

Publisher DOI:


PubMed ID:


Web of Science ID:


URI: (FactScience: 196255)

Actions (login required)

Edit item Edit item
Provide Feedback